Flexible Lifestyles for Youth (FL3X) behavioural intervention for at‐risk adolescents with Type 1 diabetes: a randomized pilot and feasibility trial. Issue 6 (30th December 2014)

• Record Type: Journal Article
• Authors: Mayer‐Davis, E. J.; Seid, M.; Crandell, J.; Dolan, L.; Lagarde, W. H.; Letourneau, L.; Maahs, D. M.; Marcovina, S.; Nachreiner, J.; Standiford, D.; Thomas, J.; Wysocki, T.
• Is Part Of: Diabetic medicine. Volume 32:Issue 6(2015:Jun.)
• Page Start: 829
• Page End: 833
• Publication Date: 2014-12-30
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.12641
• Languages: English
• ISSNs: 0742-3071

Abstract

<abstract abstract-type="main" id="dme12641-abs-0001"> <title>Abstract</title> <sec id="dme12641-sec-0001" sec-type="section"> <title>Aim</title> <p>To determine the potential effect sizes for the Flexible Lifestyle for Youth (FL3X) behavioural intervention to improve glycaemic control (HbA<sub>1c</sub>) and quality of life for at‐risk adolescents with Type 1 diabetes.</p> </sec> <sec id="dme12641-sec-0002" sec-type="section"> <title>Methods</title> <p>Participants [<italic>n </italic>=<italic> </italic>61; age 12–16 years, HbA<sub>1c</sub> 64–119 mmol/mol (8–13%)] were randomized to FL3X (minimum three sessions) or usual care. Effect sizes (Cohen's d), comparing the mean difference between the groups, were calculated.</p> </sec> <sec id="dme12641-sec-0003" sec-type="section"> <title>Results</title> <p>Study retention (95%), attendance at intervention sessions (87% attended all three sessions) and acceptability were high (100% of the adolescents and 91% of parents would recommend the programme to others). Overall, 41% of participants in the intervention group and 24% of participants in the control group were 'responders' [HbA<sub>1c</sub> decreased by > 6 mmol/mol (0.5%); d = 0.37]. HbA<sub>1c</sub> levels decreased (d = ‐0.18), diabetes‐specific quality of life increased (d = 0.29), but generic quality of life decreased (d = ‐0.23) in the intervention compared with the control group.</p> </sec> <sec id="dme12641-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The FL3X programme merits further study for improving HbA<sub>1c</sub> and diabetes‐specific quality of life in adolescents with Type 1 diabetes. (Clinical trials registry no.: NCT01286350).</p> </sec> </abstract>